Clearwater Analytics and Enfusion Complete Hart-Scott-Rodino Waiting Period
Boise, Idaho, and Chicago, Illinois – Clearwater Analytics Holdings, Inc. (Clearwater) and Enfusion, Inc. (Enfusion), two leading providers of Software-as-a-Service (SaaS) solutions for the investment management industry, have announced the completion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
About the HSR Act
The HSR Act is a US law designed to prevent anticompetitive mergers and acquisitions that may adversely impact competition and consumers. The waiting period requires companies to submit their merger or acquisition plans to the Antitrust Division of the U.S. Department of Justice and the Federal Trade Commission for review. The review process ensures that the merger or acquisition does not violate antitrust laws.
Clearwater and Enfusion Merger
Clearwater and Enfusion announced their intention to merge in a business combination transaction on November 1, 2021. The merger will create a leading global provider of SaaS-based investment management, accounting, reporting, and analytics solutions. The transaction is expected to close in the first quarter of 2022, subject to customary closing conditions.
Impact on Clearwater and Enfusion Customers
The completion of the HSR waiting period is a significant milestone in the merger process. Clearwater and Enfusion customers can expect enhanced and expanded offerings from the combined company, as the two firms have complementary product lines and customer bases. The merger will enable the companies to invest in research and development, expand their geographic reach, and enhance their customer support capabilities.
Impact on the Investment Management Industry
The merger of Clearwater and Enfusion is expected to have a positive impact on the investment management industry. The combined company will offer a comprehensive suite of SaaS-based solutions for investment management, accounting, reporting, and analytics. This will enable investment managers to streamline their operations, improve their reporting capabilities, and make more informed investment decisions.
Conclusion
The completion of the HSR waiting period is a significant step forward in the Clearwater and Enfusion merger process. The merger is expected to create a leading global provider of SaaS-based investment management, accounting, reporting, and analytics solutions. Clearwater and Enfusion customers can look forward to enhanced and expanded offerings, while the investment management industry will benefit from a more comprehensive suite of SaaS-based solutions. The merger is expected to close in the first quarter of 2022, subject to customary closing conditions.
- Clearwater and Enfusion have completed the waiting period under the HSR Act.
- The merger is expected to create a leading global provider of SaaS-based investment management solutions.
- The merger will enable the companies to invest in research and development, expand their geographic reach, and enhance their customer support capabilities.
- Clearwater and Enfusion customers can look forward to enhanced and expanded offerings.
- The investment management industry will benefit from a more comprehensive suite of SaaS-based solutions.
